Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Small GTPases and cell cycle regulation.

× No keyword cloud information.

8 in total

1. Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2.

Authors: Azucena Esparís-Ogando; Elena Díaz-Rodríguez; Juan Carlos Montero; Laura Yuste; Piero Crespo; Atanasio Pandiella
Journal: Mol Cell Biol Date: 2002-01 Impact factor: 4.272

2. Functional specificity of ras isoforms: so similar but so different.

Authors: Esther Castellano; Eugenio Santos
Journal: Genes Cancer Date: 2011-03

3. Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients.

Authors: Hong Shen; Ying Yuan; Han-Guang Hu; Xian Zhong; Xiao-Xian Ye; Mo-Dan Li; Wei-Jia Fang; Shu Zheng
Journal: World J Gastroenterol Date: 2011-02-14 Impact factor: 5.742

4. Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma.

Authors: Kshama Gupta; Jeremy C Jones; Virginea De Araujo Farias; Yuri Mackeyev; Pankaj K Singh; Alfredo Quiñones-Hinojosa; Sunil Krishnan
Journal: Front Oncol Date: 2022-05-18 Impact factor: 5.738

5. Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study.

Authors: Adam Naguib; Panagiota N Mitrou; Laura J Gay; James C Cooke; Robert N Luben; Richard Y Ball; Alison McTaggart; Mark J Arends; Sheila A Rodwell
Journal: BMC Cancer Date: 2010-03-16 Impact factor: 4.430

Small GTPases and cell cycle regulation.

1. Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2.

2. Functional specificity of ras isoforms: so similar but so different.

3. Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients.

4. Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma.

5. Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study.

Review 6. Targeting CDK4 and CDK6: From Discovery to Therapy.

7. Casein kinase iγ2 impairs fibroblasts actin stress fibers formation and delays cell cycle progression in g1.

Review 8. A perspective on the early days of RAS research.